Autologous muscle‐derived cells for the treatment of female stress urinary incontinence: A 2‐year follow‐up of a polish investigation

DOI Web Site Web Site 1 Citations
  • Klaudia Stangel‐Wojcikiewicz
    Department of Gynaecology and Oncology Jagiellonian University Collegium Medicum Cracow Poland
  • Danuta Jarocha
    Department of Transplantation Jagiellonian University Collegium Medicum Cracow Poland
  • Monika Piwowar
    Department of Bioinformatics and Telemedicine Jagiellonian University Collegium Medicum Cracow Poland
  • Robert Jach
    Department of Gynaecology and Oncology Jagiellonian University Collegium Medicum Cracow Poland
  • Tadeusz Uhl
    Faculty of Mechanical Engineering and Robotics AGH University of Science and Technology Cracow Poland
  • Antoni Basta
    Department of Gynaecology and Oncology Jagiellonian University Collegium Medicum Cracow Poland
  • Marcin Majka
    Department of Transplantation Jagiellonian University Collegium Medicum Cracow Poland

Search this article

Description

<jats:title>Abstract</jats:title><jats:sec><jats:title>Aims</jats:title><jats:p>We evaluated the safety, feasibility and initial effects of therapy with muscle‐derived cells (MDCs) for women with stress urinary incontinence (SUI).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>MDCs were isolated from an upper‐arm muscle biopsy from 16 women with SUI. Cells were isolated by enzymatic digestion and expanded in vitro for 8–10 weeks. A quantity of 0.6–25 × 10<jats:sup>6</jats:sup> of the obtained cells were injected transurethrally into the urethral rhabdosphincter of women under local anesthesia. The cells were placed circumferentially at the 9, 12, and 3 O'clock positions with endoscopic guidance.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The initial results of the treatment of SUI with adult muscle‐derived stem cells demonstrate the safety and feasibility of using these cells. The 2‐year follow‐up revealed a 75% success rate, with some patients achieving complete improvement (50%) and some patients achieving partial improvement (25%), suggesting that the prospects for this method are encouraging.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Stem cell therapy promises to become a minimally invasive method for the regeneration of the urethral rhabdosphincter muscle. Injecting a small number of cells does not preclude obtaining the desired therapeutic result. <jats:italic>Neurourol. Urodynam. 33:324–330, 2014</jats:italic>. © 2013 Wiley Periodicals, Inc.</jats:p></jats:sec>

Journal

Citations (1)*help

See more

Report a problem

Back to top